Statins and Type 2 Diabetes Mellitus: An Update After 1 Year

Author(s): Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis, Dimitri P. Mikhailidis

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 18 , 2016

Become EABM
Become Reviewer


In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.

Keywords: IMPROVE-IT, diabetes mellitus, cancer, statins, new onset diabetes, ezetimibe.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 05 May, 2016
Page: [2723 - 2725]
Pages: 3
DOI: 10.2174/1381612822666160125114626
Price: $65

Article Metrics

PDF: 30
PRC: 1